Alphabet unit Verily has taken part in an oversubscribed series B round that will fund Mammoth Biosciences' expansion from diagnostics to gene editing and drug development.
US-based disease diagnostics technology developer Mammoth Biosciences secured $45m in series B funding yesterday from investors including internet and technology conglomerate Alphabet’s life sciences research arm, Verily.
Life sciences investment firm Decheng Capital led the oversubscribed round, which was also backed by Mayfield, NFX, Plum Alley Investments, Pacific 8 Ventures, aMoon and private investor Brook Byers.
Mammoth is developing disease detection systems using Crispr DNA technology, although it focuses on the Cas14 enzyme rather than the Cas9 enzyme typically utilised…
